Ocular Therapeutix Inc
0 DAYS LEFT TO SEEK LEAD PLAINTIFF STATUS
Case Summary | |
Company Name: | Ocular Therapeutix Inc |
Stock Symbol : | NASDAQ: OCUL |
Class Period Start: | 05/05/2017 |
Class Period End: | 07/06/2017 |
Lead Plaintiff motion: | 09/05/2017 |
Date Filed: | 07/07/2017 |
Type of Case: | Securities Class Action |
Court: | U.S. District Court for the District of New Jersey |
Summary: | Thieler Law Corp advises investors with losses exceeding $100,000 of the September 5, 2017 lead plaintiff deadline in a class action lawsuit filed against Ocular Therapeutix Inc (NASDAQ: OCUL) (“Ocular” or “the Company”). The suit is pending in the U.S. District Court for the District of New Jersey and investors, who purchased Ocular Therapeutix Inc securities between May 5, 2017 and July 6, 2017, have until September 5, 2017 to move for lead plaintiff. You do not need to move for lead plaintiff to be a member of the Class. If you purchased Ocular Therapeutix Inc securities during the Class Period, and have losses over $100,000, you may contact Thieler Law Corp by calling at (619) 377 - 4324 or emailing mail@thielerlaw.com . No class has been certified in this case, and if your losses are less than $100,000 you are still a member of the class. The complaint alleges that during the Class Period defendants made false and misleading statements and/or allegedly failed to disclose that Ocular was experiencing significant manufacturing issues with respect to DEXTENZA, including that more than 50% of lots manufactured by Ocular Therapeutix contained bad product; such manufacturing issues could imperil DEXTENZA's approval by the FDA; and as a result, Ocular's public statements were materially false and misleading at all relevant times. On May 5, 2017, Ocular revealed that the U.S. Food and Drug Administration had found minor issues at its manufacturing plant. On July 6, 2017, an article published by Seeking Alpha stated that Ocular's management had been misleading investors about manufacturing issues, alleging that more than 50% of lots manufactured by Ocular contain bad product. On this news, NASDAQ: OCUL fell $0.68 per share or over 6% to close at $9.50 per share on July 6, 2017. If you were negatively impacted by your investment in Ocular Therapeutix Inc securities between May 5, 2017 and July 6, 2017 and would like to learn more about this lawsuit and your ability to participate as a lead plaintiff, please contact us for your no-cost evaluation. Thieler Law Corp purchases advertisements on search engines, social media sites and other websites. If you send us information, note that does not create an attorney-client relationship with the firm. Thieler Law Corp 2534 State Street - Suite 406, San Diego, CA 92101 by email: mail@thielerlaw.com or telephone at +1 (619) 377 - 4324 or visit our website http://www.thielerlaw.com/ or Facsimile: +1 (619) 785 – 3185 |